Overview

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Status:
Terminated

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received treatment for their chronic hepatitis C (HCV) genotype 1 infection.

Phase:

Phase 3

Details

Lead Sponsor:

Debiopharm International SA

Treatments:

Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin